SCHEMBL1713792

SCHEMBL1713792

Cn1c(=O)[nH]c2ncccc2c1=O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FEN1 P39748 1/20 0.66
ALDH1A1 P00352 3/20 0.60
ADORA2A P29274 2/20 0.54
ADORA2B P29275 2/20 0.54
AURKA O14965 1/20 0.54
PARP1 P09874 1/20 0.54
ADORA3 P0DMS8 1/20 0.54
ADORA1 P30542 1/20 0.54
MAPT P10636 2/20 0.52
KDM4E B2RXH2 3/20 0.51
PKM P14618 2/20 0.51
HTT P42858 1/20 0.51
POLB P06746 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
LOXL3 P58215 1/20 0.50
LOXL2 Q9Y4K0 1/20 0.50
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
DAO P14920 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7011325 0.83 MAPT (0.64) FEN1ALDH1A1MAPTKDM4EPKM
SCHEMBL8145246 0.79 FEN1 (1.00) FEN1ALDH1A1ADORA2AAURKAPARP1
SCHEMBL1713392 0.79 FEN1 (0.60) FEN1ALDH1A1ADORA2AADORA2BADORA3
SCHEMBL22017502 0.79 FEN1 (0.60) FEN1ALDH1A1AURKAPARP1MAPT
SCHEMBL11865926 0.79 FEN1 (0.60) FEN1ALDH1A1AURKAPARP1MAPT
SCHEMBL29407515 0.79 FEN1 (0.60) FEN1ALDH1A1AURKAPARP1MAPT
SCHEMBL1163568 0.79 DAO (0.64) FEN1ALDH1A1ADORA2AADORA2BAURKA
SCHEMBL29745083 0.79 DAO (0.64) FEN1ALDH1A1ADORA2AADORA2BAURKA
SCHEMBL1713804 0.78 HTT (0.64) FEN1ALDH1A1AURKAPARP1MAPT
SCHEMBL11872109 0.77 MAPT (0.76) FEN1ALDH1A1ADORA2AADORA2BADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8192918-B2 Lithographic printing plate precursor AGFA GRAPHICS NV (BE) 2012-06-05 US disclosed
US-8192918-B2 Lithographic printing plate precursor AGFA GRAPHICS NV (BE) 2012-06-05 US disclosed
US-8192918-B2 Lithographic printing plate precursor AGFA GRAPHICS NV (BE) 2012-06-05 US disclosed
EP-1985445-B1 A lithographic printing plate precursor AGFA GRAPHICS NV (BE) 2011-07-20 EP disclosed
EP-1985445-B1 A lithographic printing plate precursor AGFA GRAPHICS NV (BE) 2011-07-20 EP disclosed
US-20100112476-A1 A LITHOGRAPHIC PRINTING PLATE PRECURSOR AGFA GRAPHICS NV (BE) 2010-05-06 US disclosed
US-20100112476-A1 A LITHOGRAPHIC PRINTING PLATE PRECURSOR AGFA GRAPHICS NV (BE) 2010-05-06 US disclosed
US-20100112476-A1 A LITHOGRAPHIC PRINTING PLATE PRECURSOR AGFA GRAPHICS NV (BE) 2010-05-06 US disclosed
WO-2008132091-A1 A LITHOGRAPHIC PRINTING PLATE PRECURSOR AGFA GRAPHICS NV (BE) 2008-11-06 WO disclosed
EP-1985445-A1 A lithographic printing plate precursor Agfa Graphics N.V. (BE) 2008-10-29 EP disclosed
EP-1985445-A1 A lithographic printing plate precursor Agfa Graphics N.V. (BE) 2008-10-29 EP disclosed
US-7435743-B2 Pyridine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2008-10-14 US disclosed
US-7435743-B2 Pyridine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2008-10-14 US disclosed
US-7232909-B2 Pyridine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2007-06-19 US disclosed
US-7232909-B2 Pyridine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2007-06-19 US disclosed
US-6774134-B2 FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION BRISTOL-MYERS SQUIBB COMPANY 2004-08-10 US disclosed
US-6774134-B2 FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION BRISTOL-MYERS SQUIBB COMPANY 2004-08-10 US disclosed
US-6774134-B2 FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION BRISTOL-MYERS SQUIBB COMPANY 2004-08-10 US disclosed
US-20020099208-A1 Heterocyclic substituted 2-methyl-benzimidazole antiviral agents BRISTOL-MYERS SQUIBB COMPANY 2002-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099208-A1 Heterocyclic substituted 2-methyl-benzimidazole antiviral agents MAVS, ZC3HAV1, EIF2AK2 FEN1 636/4885ALDH1A1 2968/4885ADORA2A 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.